Money
Filter News
Found 84,372 articles
-
Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.
-
Follow along as BioSpace keeps you up to date on the latest pharma and biotech M&As, from announcements to closings.
-
TCBP Announces Exercise of Series D Warrants For Cash
3/18/2024
TC BioPharm PLC announced that an institutional investor has exercised cash only warrants represented 623,750 American Depository Shares at an exercise price of $2.02.
-
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas - March 18, 2024
3/18/2024
CytomX Therapeutics, Inc. today announced that the first clinical candidate in its TCB agreement with Astellas has entered into GLP toxicology studies which triggers a $5 million payment to CytomX.
-
ConKay Medical Systems Raises $1.8M in Oversubscribed Seed Funding Round
3/18/2024
ConKay Medical Systems, a medtech start-up company developing a unique device for treating patients suffering from valvular regurgitation, has closed an oversubscribed $1.8M seed round.
-
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
3/18/2024
Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
-
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
3/18/2024
AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease, including those who are uninsured and underinsured.
-
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
3/18/2024
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a $175 million five-year, term loan facility with Hercules Capital, Inc.
-
Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
3/18/2024
Acurx Pharmaceuticals, Inc. announced certain financial and operational results for the fourth quarter and full year ended December 31, 2023.
-
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
3/18/2024
Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the fourth quarter and year ended December 31, 2023.
-
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - March 18, 2024
3/18/2024
EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.
-
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
3/18/2024
BiomX Inc. announced the closing of its previously announced acquisition of Adaptive Phage Therapeutics, Inc. and its previously announced $50 million private placement to certain institutional accredited investors, which was led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital.
-
Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress
3/18/2024
Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced fourth quarter and full year financial results for the period ended December 31, 2023, and an overview of the Company’s progress.
-
Cambrex Nears Completion of 5-year, $100-Million-Dollar Investment Plan, One Year Ahead of Schedule
3/18/2024
Cambrex, a leading global contract development and manufacturing organization, announced that it is nearing the completion of a 5-year, $100-million-dollar investment strategy, one year ahead of schedule.
-
Spineart Secures more than CHF20 Million in Convertible Financing Following Completion of BAGUERA®C IDE Studies Enrollment
3/18/2024
Spineart, a global spine specialist working with surgeons to accelerate the adoption of cutting-edge technologies, has successfully raised a CHF20 million convertible financing.
-
Carlsmed Raises $52.5M in Series C Financing to Advance Personalized Spine Surgery
3/18/2024
Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners.
-
SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
3/18/2024
SENISCA, an award-winning biotechnology company developing RNA-based senotherapeutics to treat age-related disease, announces it has raised an additional £3.7 million in funding.
-
Strong Fourth Quarter Powers 2023 Kelyniam Financials
3/17/2024
Kelyniam Global, a maker of custom cranial implants, announced results for its year ended December 31, 2023.
-
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
3/16/2024
ProSomnus, Inc. announced it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call.
-
Asgard Therapeutics, a Swedish gene therapy biotech, has closed a $32 million Series A round with help from prominent pharma players as it prepares for a 2026 IND.